CN105813652A - 用于糖尿病治疗的可注射纳米网络凝胶 - Google Patents

用于糖尿病治疗的可注射纳米网络凝胶 Download PDF

Info

Publication number
CN105813652A
CN105813652A CN201480037463.3A CN201480037463A CN105813652A CN 105813652 A CN105813652 A CN 105813652A CN 201480037463 A CN201480037463 A CN 201480037463A CN 105813652 A CN105813652 A CN 105813652A
Authority
CN
China
Prior art keywords
insulin
particles
glucose
particle
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480037463.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·G·安德森
顾臻
A·A·艾梅蒂
R·S·兰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Massachusetts Institute of Technology
Original Assignee
Boston Childrens Hospital
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Massachusetts Institute of Technology filed Critical Boston Childrens Hospital
Publication of CN105813652A publication Critical patent/CN105813652A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
CN201480037463.3A 2013-04-30 2014-04-29 用于糖尿病治疗的可注射纳米网络凝胶 Pending CN105813652A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817752P 2013-04-30 2013-04-30
US61/817,752 2013-04-30
US201361864069P 2013-08-09 2013-08-09
US61/864,069 2013-08-09
PCT/US2014/035927 WO2014179344A1 (en) 2013-04-30 2014-04-29 Injectable nano-network gels for diabetes treatment

Publications (1)

Publication Number Publication Date
CN105813652A true CN105813652A (zh) 2016-07-27

Family

ID=51843897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480037463.3A Pending CN105813652A (zh) 2013-04-30 2014-04-29 用于糖尿病治疗的可注射纳米网络凝胶

Country Status (11)

Country Link
US (1) US20160067190A1 (cg-RX-API-DMAC7.html)
EP (1) EP2991673A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016517885A (cg-RX-API-DMAC7.html)
KR (1) KR20160024853A (cg-RX-API-DMAC7.html)
CN (1) CN105813652A (cg-RX-API-DMAC7.html)
AU (1) AU2014260024B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015027561A8 (cg-RX-API-DMAC7.html)
HK (2) HK1222546A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015015079A (cg-RX-API-DMAC7.html)
RU (1) RU2015151135A (cg-RX-API-DMAC7.html)
WO (1) WO2014179344A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106668840A (zh) * 2017-02-10 2017-05-17 南通大学 一种胰岛素控释药物及其制备方法与应用
WO2020088306A1 (zh) * 2018-10-31 2020-05-07 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
CN111343970A (zh) * 2017-09-13 2020-06-26 北卡罗莱纳州立大学 微针贴片局部诱导脂肪组织褐变治疗肥胖症
CN115350267A (zh) * 2022-07-19 2022-11-18 深圳大学 一种级联催化型纳米治疗剂及其制备方法和应用
CN116474162A (zh) * 2023-04-28 2023-07-25 吉林大学 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
CN104740641B (zh) * 2015-04-08 2019-02-01 烟台大学 一种糖敏感的缓控释微球组合物及其制备方法
BR112017022535A2 (pt) * 2015-04-21 2018-07-10 Univ North Carolina State sistema de liberação de insulina responsivo à glicose usando nanocompósitos sensíveis à hipóxia.
CN113730605A (zh) * 2016-07-21 2021-12-03 波士顿科学国际有限公司 可注射组合物
US11351230B2 (en) 2016-11-07 2022-06-07 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
WO2018106696A1 (en) * 2016-12-05 2018-06-14 North Carolina State University Core-shell microneedle devices and uses thereof
EP3713594A4 (en) 2017-11-21 2021-11-03 North Carolina State University LOADABLE POLYMERIC DEPOT FOR GLUCOSE-TRIGGERED INSULIN DELIVERY WITH ULTRA-FAST REACTION
EP3735262A4 (en) * 2018-01-03 2021-09-29 Penn State Research Foundation GLUCOSE OXIDASE COMPOSITIONS USED AS AN ANTI-CONVULSIVER IN NEWBORNS
WO2020219880A2 (en) * 2019-04-25 2020-10-29 Massachusetts Institute Of Technology Cyclodextrin supramolecular scaffolds and uses thereof
WO2025024243A1 (en) * 2023-07-21 2025-01-30 Massachusetts Institute Of Technology Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed-loop prophylactic treatment of hypoglycemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056311A2 (en) * 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
AU3360197A (en) * 1996-07-01 1998-01-21 Universiteit Utrecht Hydrolysable hydrogels for controlled release
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
EP1595534A1 (en) * 2004-05-13 2005-11-16 Universiteit Utrecht Holding B.V. Gel composition comprising charged polymers
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US20110189299A1 (en) * 2008-07-01 2011-08-04 Nitto Denko Corporation Pharmaceutical composition containing surface-coated microparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056311A2 (en) * 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QUN WANGA, SYED JAMALB, MICHAEL S. DETAMOREA, AND CORY BERKLANDA: "PLGA-chitosan/PLGA-alginate Nanoparticle Blends as Biodegradable Colloidal Gels for Seeding Human Umbilical Cord Mesenchymal Stem Cells", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A》 *
YONGHAO WU, HUAMIN HU, JINMING HU AND SHIYONG LIU: "Glucose-Regulated Insulin Release from Acid-Disintegrable Microgels Covalently Immobilized with Glucose Oxidase and Catalase", 《MACROMOLECULAR RAPID COMMUNICATIONS》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106668840A (zh) * 2017-02-10 2017-05-17 南通大学 一种胰岛素控释药物及其制备方法与应用
CN106668840B (zh) * 2017-02-10 2020-02-14 南通大学 一种胰岛素控释药物及其制备方法与应用
CN111343970A (zh) * 2017-09-13 2020-06-26 北卡罗莱纳州立大学 微针贴片局部诱导脂肪组织褐变治疗肥胖症
WO2020088306A1 (zh) * 2018-10-31 2020-05-07 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
CN111195238A (zh) * 2018-10-31 2020-05-26 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
CN115350267A (zh) * 2022-07-19 2022-11-18 深圳大学 一种级联催化型纳米治疗剂及其制备方法和应用
CN116474162A (zh) * 2023-04-28 2023-07-25 吉林大学 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法

Also Published As

Publication number Publication date
KR20160024853A (ko) 2016-03-07
EP2991673A1 (en) 2016-03-09
RU2015151135A (ru) 2017-06-02
HK1222546A1 (zh) 2017-07-07
JP2016517885A (ja) 2016-06-20
EP2991673A4 (en) 2016-12-21
BR112015027561A8 (pt) 2019-12-24
US20160067190A1 (en) 2016-03-10
AU2014260024A1 (en) 2015-11-19
MX2015015079A (es) 2016-07-05
HK1221415A1 (zh) 2017-06-02
BR112015027561A2 (pt) 2017-07-25
AU2014260024B2 (en) 2016-09-15
WO2014179344A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
AU2014260024B2 (en) Injectable nano-network gels for diabetes treatment
US20220160841A1 (en) Glucose-responsive insulin delivery microneedle system
US9339529B2 (en) Glucose-responsive microgels for closed loop insulin delivery
JP4814107B2 (ja) 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
EP1595534A1 (en) Gel composition comprising charged polymers
CN103622902B (zh) 一种温敏凝胶药物制剂及其制备方法
Li et al. Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment
US20210128738A1 (en) Insulin-responsive glucagon delivery patch
US8449915B1 (en) Pharmaceutical composition of nanoparticles
Sona NANOPARTICULATE DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF DIABETES.
Yadav et al. Modulation of physicochemical properties of polymers for effective insulin delivery systems
Shah et al. Strategies for Formulation and Systemic Delivery of Therapeutic Proteins
Patra et al. Stimuli-responsive polymers for treatment of diabetes mellitus
Fuchs Bioengineering glucose-responsive cannulas for electronics-free, automated insulin delivery
Subramani NPDDS for the treatment of diabetes
US20240382566A1 (en) A glucose-sensitive insulin-loaded microparticle
SHARMA et al. RECENT APPROACHES IN GLUCOSE RESPONSIVE INSULIN DELIVERY SYSTEM
CN110179997A (zh) 一种用于糖尿病治疗的纳米药物载体及其组合药物
Baieli et al. 3 Biomedical applications of hydrogels in the form of nano-and microparticles
WO2025024455A1 (en) Compositions and methods for delivery of therapeutic peptides
da Fonseca Establishment of bioengineered glucose-responsive nanoparticles for type 2 diabetes mellitus therapy
JP2007326833A (ja) 親水性活性物質含有微粒子の製造方法
KR20070031931A (ko) 하전된 폴리머를 포함하는 겔 조성물
US20140199369A1 (en) Pharmaceutical composition
HK1245105B (en) Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221415

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160727

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1221415

Country of ref document: HK